Leukemia: AML, ALL, CML & CLL Types and Treatment

Leukemia starts in the bone marrow, the spongy tissue inside bones where blood cells are made. Normally, the marrow produces red blood cells, white blood cells, and platelets in a controlled, orderly way. In leukemia, a genetic change occurs in an early blood-forming cell, causing it to multiply uncontrollably and fail to mature properly. These abnormal cells, sometimes called blasts, crowd out normal blood cell production and can spill into the bloodstream, and in some cases infiltrate the spleen, liver, lymph nodes, or central nervous system.

Leukemias are classified along two axes. The first is cell lineage: myeloid leukemias arise from the cells that normally develop into red cells, platelets, and certain white cells (granulocytes, monocytes), while lymphoid leukemias arise from lymphocyte precursors, the cells involved in immune defence. The second axis is how quickly the disease develops: acute leukemias arise suddenly from immature blast cells and progress rapidly without treatment, while chronic leukemias develop from more mature-looking cells and typically progress slowly, sometimes over years.

Combining these two axes gives the four major types of leukemia. Acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) are aggressive diseases of immature cells that usually require prompt, intensive treatment. Chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL) generally progress more gradually and, particularly for CLL, may not need immediate treatment at diagnosis.

AML is the most common acute leukemia in adults, with incidence rising with age, while ALL is more common in children, though it also occurs in adults, often with a more difficult course. CML almost always involves a specific genetic abnormality called the Philadelphia chromosome, which fuses two genes (BCR and ABL1) into a driver of the disease. CLL is the most common form of leukemia in older adults in Western countries and often causes no symptoms for years before it is found incidentally on routine blood tests.

Each of these leukemias further divides into subtypes based on the specific mutations, chromosomal abnormalities, and cell surface markers present, which is why comprehensive laboratory testing at diagnosis has become so important. Two people with the same broad leukemia label can have very different biology, prognosis, and treatment recommendations depending on these findings.

A leukemia diagnosis can feel overwhelming, particularly because the terminology (AML, ALL, CML, CLL) can be confusing at first. It is important to understand exactly which subtype you or your loved one has, since this single piece of information shapes almost everything that follows: how urgently treatment is needed, what treatment options exist, and what the likely course of the disease will be.

Unlike many solid tumours, leukemia is a disease of the whole blood and marrow system rather than a localised mass, so the concept of a tumour that can be surgically removed generally does not apply. Instead, treatment aims to eliminate or control the abnormal cell population throughout the body, using drugs, and in some cases a stem cell (bone marrow) transplant. Ask your care team to clearly identify your leukemia type and any specific genetic markers found, as these details determine your personalised treatment plan.

Symptoms of acute leukemia (AML and ALL) often develop over days to a few weeks and reflect the crowding out of normal blood cells: fatigue and pale skin from anemia (low red blood cells), frequent infections or fevers from a shortage of functioning white blood cells, and easy bruising, bleeding gums, or petechiae (small red spots) from low platelet counts. Bone or joint pain, swollen lymph nodes, and an enlarged spleen or liver causing abdominal fullness can also occur. Because these symptoms develop quickly, acute leukemia is often diagnosed after an urgent visit to a doctor or emergency department.

Chronic leukemias tend to have a much more gradual, sometimes silent, onset. Many people with CML or CLL have no symptoms at all and are diagnosed after an abnormal white blood cell count is noticed on a routine blood test. When symptoms do occur, they may include fatigue, unintentional weight loss, night sweats, low-grade fevers, and a feeling of fullness or discomfort in the upper left abdomen due to an enlarged spleen. Swollen, painless lymph nodes are particularly common in CLL.

Because many of these symptoms overlap with common, non-cancerous conditions, leukemia is not always suspected immediately. Persistent, unexplained fatigue, recurrent infections, easy bruising or bleeding, or unexplained fevers and weight loss should prompt a medical evaluation, including a complete blood count.

Leukemia develops when a blood-forming stem cell or early progenitor cell acquires genetic mutations that disrupt the normal controls on cell growth, maturation, and survival. In most cases these mutations are acquired during a person's lifetime rather than inherited, meaning they arise from DNA damage in a single cell that then multiplies into a population of abnormal cells. The exact trigger for these mutations is often unknown in an individual patient.

In CML, the driving abnormality is well defined: a translocation between chromosomes 9 and 22 creates the Philadelphia chromosome, which produces an abnormal fusion protein, BCR-ABL1, that continuously signals cells to divide. This discovery directly led to the development of targeted drugs that block this protein. In AML and ALL, a wider range of genetic abnormalities can be involved, including mutations in genes such as FLT3, NPM1, IDH1/IDH2, and TP53 in AML, and various chromosomal rearrangements or mutations in ALL, including some that also involve BCR-ABL1 (so-called Philadelphia chromosome-positive ALL). CLL is associated with characteristic chromosomal changes such as deletion of 13q, 11q, or 17p, and mutations in genes like TP53, which affect both prognosis and treatment choice.

Secondary leukemias can also arise after previous chemotherapy or radiation therapy for another cancer, reflecting DNA damage from those treatments. In general, leukemia is not contagious and is not something a patient did or could have prevented in the vast majority of cases.

Established risk factors for leukemia include prior chemotherapy or radiation therapy, exposure to high doses of ionising radiation, and workplace or environmental exposure to benzene and certain other chemicals. Smoking is associated with a modestly increased risk of AML. Certain inherited genetic conditions, such as Down syndrome, Fanconi anemia, and some inherited bone marrow failure syndromes, raise the risk of acute leukemia, particularly in children.

Age is a significant factor: ALL is most common in children and young adults, while AML, CML, and especially CLL become more common with increasing age. A family history of leukemia or certain blood disorders may slightly increase risk, though most leukemia is not considered a directly inherited disease. Having myelodysplastic syndrome or another blood disorder can also increase the risk of AML developing over time.

It is worth emphasising that most people who develop leukemia have no identifiable risk factor, and most people with known risk factors never develop leukemia. Unlike many solid tumours, there are currently no widely recommended lifestyle changes proven to meaningfully lower leukemia risk, beyond avoiding known chemical and radiation exposures where possible.

Leukemia is typically first suspected based on an abnormal complete blood count, which may show too many or too few white blood cells, low red blood cells, or low platelets, sometimes alongside circulating blast cells seen under the microscope. A peripheral blood smear, examined by a pathologist, can reveal characteristic abnormal cells that point toward a specific leukemia type.

Confirming the diagnosis almost always requires a bone marrow aspiration and biopsy, a procedure in which a sample of marrow, usually from the hip bone, is examined for the percentage and appearance of abnormal cells. Flow cytometry is used to identify specific proteins on the surface of the abnormal cells (immunophenotyping), which helps distinguish myeloid from lymphoid leukemia and identifies specific subtypes.

Cytogenetic analysis (karyotyping) and fluorescence in situ hybridisation (FISH) testing look for chromosomal abnormalities such as the Philadelphia chromosome or deletions associated with CLL, while molecular testing, including next-generation sequencing (NGS), identifies specific gene mutations relevant to prognosis and treatment, such as FLT3 or NPM1 in AML.

Additional tests may include a lumbar puncture to check for leukemia cells in the cerebrospinal fluid, particularly in ALL, and imaging studies to assess organ involvement or lymph node enlargement. Because leukemia affects the whole marrow and blood system rather than forming a single localised tumour, this combination of blood, marrow, and genetic testing, rather than imaging alone, forms the core of diagnosis and risk assessment.

Leukemia does not use the TNM staging system that applies to solid tumours, because it is a disease of the blood and marrow rather than a localised mass. Instead, each leukemia type uses its own system to classify risk and, in some cases, disease extent.

For CLL, two related staging systems are used: the Rai system (stages 0 through IV, based on lymphocyte count, lymph node and spleen/liver enlargement, and blood counts) and the Binet system (stages A, B, and C, based on the number of enlarged lymphoid areas and the presence of anemia or low platelets), which is more commonly used in Europe. Both systems group patients into low, intermediate, and high-risk categories that help predict how likely the disease is to need treatment soon and how it may behave over time, though many patients with early-stage CLL are simply monitored (a strategy called watchful waiting) rather than treated immediately.

For AML and ALL, rather than a numeric stage, patients are classified into risk categories, often favourable, intermediate, and adverse (or high) risk, based primarily on the specific cytogenetic and molecular abnormalities found in the leukemia cells, along with factors such as age and response to initial treatment. For example, AML with certain favourable genetic markers such as NPM1 mutation without FLT3-ITD, or specific translocations, tends to respond better to standard chemotherapy, while AML with TP53 mutations or complex chromosomal changes is considered higher risk and may prompt earlier consideration of stem cell transplant.

CML is generally described by phase rather than stage: chronic phase (the most common presentation, with a relatively low proportion of blast cells), accelerated phase, and blast phase (which behaves like an acute leukemia and is more difficult to treat). The vast majority of CML is diagnosed in chronic phase, particularly where routine blood testing is common, and modern targeted therapy aims to keep the disease in this more manageable phase indefinitely.

Genetic and molecular testing has become one of the most important parts of leukemia care because it directly informs both prognosis and treatment selection. In AML, testing typically includes cytogenetics and a molecular panel covering genes such as FLT3, NPM1, IDH1, IDH2, TP53, CEBPA, and others; several of these, including FLT3 and IDH1/IDH2 mutations, can now be targeted with specific oral drugs alongside or after chemotherapy.

In ALL, testing looks for the Philadelphia chromosome (BCR-ABL1) and other recurrent genetic rearrangements, since Philadelphia chromosome-positive ALL is treated with the same class of targeted drugs used in CML, combined with chemotherapy or, in some cases, immunotherapy. Measurable residual disease (MRD) testing, which detects very small numbers of remaining leukemia cells after treatment using highly sensitive flow cytometry or molecular methods, is increasingly used in both AML and ALL to assess depth of remission and guide decisions about further treatment, including transplant.

In CML, quantitative PCR testing for the BCR-ABL1 transcript is used not only to diagnose the disease but to monitor response to treatment over time, since achieving specific molecular response milestones is linked to long-term outcomes. In CLL, testing for chromosomal deletions (particularly 17p and 11q) and TP53 mutations, along with IGHV mutation status, helps predict how the disease will behave and which treatments are likely to be most effective, since 17p deletion or TP53 mutation generally indicates a more difficult-to-treat disease that benefits from targeted, non-chemotherapy approaches.

Acute myeloid leukemia (AML) is a fast-growing cancer of myeloid precursor cells and includes multiple subtypes defined by the World Health Organization classification, based largely on specific genetic abnormalities rather than only microscopic appearance; some subtypes, such as acute promyelocytic leukemia (APL), have a distinct biology and a highly effective targeted treatment approach using all-trans retinoic acid and arsenic trioxide rather than standard intensive chemotherapy.

Acute lymphoblastic leukemia (ALL) arises from lymphoid precursor cells and is classified as B-cell or T-cell ALL, with further subtypes based on genetic features; Philadelphia chromosome-positive ALL is an important subtype because it responds to the same targeted drugs used in CML. ALL is most common in children, in whom cure rates are generally high, but it also occurs in adults, where outcomes have improved with the incorporation of targeted and immune-based therapies.

Chronic myeloid leukemia (CML) is almost always defined by the presence of the Philadelphia chromosome and BCR-ABL1 fusion, with disease phase (chronic, accelerated, or blast) describing how advanced it is rather than distinct subtypes. Chronic lymphocytic leukemia (CLL), closely related to a condition called small lymphocytic lymphoma (the same disease when it presents mainly in lymph nodes rather than blood), is subclassified by genetic and molecular features, particularly TP53 status and IGHV mutation status, which strongly influence prognosis and treatment selection.

Treatment for AML typically begins with induction chemotherapy aimed at achieving remission, often followed by consolidation chemotherapy or, for higher-risk disease, an allogeneic stem cell transplant from a matched donor. Patients with specific mutations such as FLT3 or IDH1/IDH2 may receive targeted oral drugs in combination with chemotherapy, and older or less fit patients may be offered lower-intensity combinations, such as venetoclax with a hypomethylating agent, which can be effective with fewer side effects than intensive chemotherapy. APL is treated very differently, using all-trans retinoic acid and arsenic trioxide, which achieves high cure rates without traditional intensive chemotherapy in most cases.

ALL treatment involves multi-phase chemotherapy regimens (induction, consolidation, and maintenance) that can extend over one to two years, with central nervous system-directed therapy to prevent or treat leukemia in the spinal fluid. Philadelphia chromosome-positive ALL adds a targeted tyrosine kinase inhibitor to chemotherapy. Immunotherapies, including bispecific antibodies such as blinatumomab and CAR T-cell therapy, have become important options, particularly for relapsed or hard-to-treat ALL, and stem cell transplant may be recommended for higher-risk disease or after relapse.

CML is primarily treated with oral tyrosine kinase inhibitors (TKIs), a class of targeted drugs that block the BCR-ABL1 protein; these drugs have transformed CML from a rapidly fatal disease into one that many patients manage successfully for years, often with a good quality of life, with regular monitoring of BCR-ABL1 levels in the blood. Some patients who achieve a very deep, sustained response may eventually be able to attempt stopping therapy under close medical supervision, though this is not appropriate for everyone.

CLL treatment has shifted substantially toward targeted, non-chemotherapy approaches, including BTK inhibitors, BCL-2 inhibitors such as venetoclax, and monoclonal antibodies, often used alone or in combination, particularly in patients with TP53 mutation or 17p deletion, who tend to respond poorly to traditional chemotherapy. Many patients with early-stage, asymptomatic CLL do not require immediate treatment and are instead monitored regularly (watchful waiting) until the disease shows signs of progression. Allogeneic stem cell transplant is generally reserved for younger, fit patients with high-risk or relapsed disease across leukemia types, given its intensity and potential for significant side effects.

Survival statistics vary considerably by leukemia type, subtype, age, and genetic risk category, and all figures below are population averages from sources such as the U.S. SEER program; they cannot predict what will happen for any individual patient. For AML, overall 5-year relative survival is roughly in the 30% range across all ages combined, but this varies enormously by age and genetic risk, from considerably higher in younger patients with favourable genetics to lower in older patients or those with adverse-risk disease.

For ALL, 5-year relative survival is substantially higher in children, often exceeding 85-90%, reflecting decades of refinement in paediatric protocols, while adult ALL survival is lower, roughly in the 40-50% range overall, though improving with newer immunotherapies. CML has been transformed by targeted therapy: with modern tyrosine kinase inhibitors, many patients diagnosed in chronic phase have a life expectancy approaching that of the general population, and 5-year relative survival now exceeds 70-90% in most published series. CLL also tends to have a relatively favourable overall 5-year relative survival, often quoted above 85-90%, reflecting its typically slow course, though outcomes are notably less favourable for patients with high-risk genetic features such as TP53 mutation or 17p deletion.

These numbers continue to improve as targeted therapies, immunotherapies, and transplant techniques advance, so they may understate the outlook for someone diagnosed today or in the future. Your own prognosis depends on your specific leukemia subtype, genetic findings, age, overall health, and response to initial treatment, and is best discussed individually with your haematology-oncology team.